Selank

Overview

Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, structurally based on the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for enhanced stability and CNS activity. Selank has been approved in Russia as an anxiolytic and nootropic agent. Published research describes its unique profile combining anxiolytic effects (comparable to benzodiazepines in some animal models) without sedative, amnestic, or dependence-producing properties. The peptide has been investigated for its dual immunomodulatory and neurotropic mechanisms, distinguishing it from classical anxiolytic compounds.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

Published research describes Selank as modulating GABAergic neurotransmission through allosteric interactions with GABA-A receptors, enhancing inhibitory signaling in limbic structures. Studies describe modulation of monoamine neurotransmitter systems including serotonin, norepinephrine, and dopamine. The peptide influences BDNF expression and enkephalin metabolism through inhibition of enkephalin-degrading enzymes, potentially contributing to its anxiolytic profile. As a tuftsin analog, Selank retains immunomodulatory properties including effects on IL-6, IFN-α/γ, and other cytokines. Gene expression studies describe modulation of inflammatory, chemokine, and neurotrophic gene networks.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• Anxiolytic effects in behavioral models without sedation or dependence
• GABAergic modulation and benzodiazepine-site interactions
• Immunomodulatory properties through tuftsin-related mechanisms
• BDNF and enkephalin pathway modulation in CNS tissue
• Gene expression changes in limbic and cortical brain regions
• Cognitive function and attention in experimental paradigms

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (6 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

Published animal studies have administered Selank intranasally at doses of 100–300 μg/kg in rodent models. Clinical use in Russia employs 0.15% nasal drops (approximately 75 μg per drop). In vitro studies have used concentrations of 10 nM to 100 μM. All dosing information is from published literature only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store lyophilized Selank at -20°C. Reconstituted solutions at 2–8°C, use within 14 days. Protect from light and moisture. Handle with sterile laboratory technique.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

Selank has been approved for clinical use in Russia with an established post-marketing safety record. Published studies describe no sedation, no physical dependence, no withdrawal effects, and no amnestic properties—distinguishing it from benzodiazepines. No significant adverse effects have been reported in published preclinical studies. This compound is for laboratory research use only.

For research use only · Not FDA/EMA approved · Not for human consumption